Addpharma Inc.
Addpharma Inc.
Explore linked clinical trials.24 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Not yet recruiting | Phase 3 | 2026-09-16 | NCT07816198 | |
| A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hyperlipidemia, metabolic disease, type 2 diabetes mellitus | Not yet recruiting | Phase 1 | 2026-07-28 | NCT07730567 | |
| A Clinical Trial to Evaluate the Bioequivalence of AD-116A and AD-1161 Under Fed Conditions in Healthy Adult Male Volunteers | Genital Diseases, Male Urogenital Diseases, Urogenital Diseases, benign prostatic hyperplasia, male reproductive system disorder, prostate disorder | Not yet recruiting | Phase 1 | 2026-07-27 | NCT07722871 | |
| A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults | Digestive System Diseases, digestive system disorder, gastritis, gastroenteritis, stomach disorder | Not yet recruiting | Phase 1 | 2026-07-27 | NCT07717775 | |
| A Study to Evaluate the Safety, Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects | Chronic Heart Failure | Not yet recruiting | Phase 1 | 2026-07-21 | NCT07717749 | |
| A Clinical Trial to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers | Genital Diseases, Male Urogenital Diseases, Urogenital Diseases, benign prostatic hyperplasia, male reproductive system disorder, prostate disorder | Not yet recruiting | Phase 1 | 2026-07-20 | NCT07715305 | |
| A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy Adults | Chronic Liver Disease (CLD) | Not yet recruiting | Phase 1 | 2026-06-01 | NCT07618845 | |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, cardiovascular disorder, hypertensive disorder, metabolic disease, vascular disorder | Not yet recruiting | Phase 1 | 2026-05-15 | NCT07590167 | |
| Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee | Osteoarthritis of the Knees | Not yet recruiting | Phase 2 | 2026-04-24 | NCT07550231 | |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232 | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease | Not yet recruiting | Phase 1 | 2026-04-20 | NCT07538466 | |
| A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults | Chronic Liver Disease (CLD) | Not yet recruiting | Phase 1 | 2026-04-13 | NCT07521241 | |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects | Chronic Heart Failure | Not yet recruiting | Phase 1 | 2026-03-17 | NCT07476157 | |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects | Genital Diseases, Male Urogenital Diseases, Urogenital Diseases, benign prostatic hyperplasia, male reproductive system disorder, prostate disorder | Recruiting | Phase 1 | 2026-03-03 | NCT07444385 | |
| A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults | Digestive System Diseases, digestive system disorder, gastritis, gastroenteritis, stomach disorder | Not yet recruiting | Phase 1 | 2026-02-27 | NCT07385248 | |
| Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151' | Digestive System Diseases, digestive system disorder, duodenal disorder, gastric ulcer, intestinal disorder, peptic ulcer disease, stomach disorder | Recruiting | Phase 1 | 2026-02-11 | NCT07385235 | |
| Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322 | cardiovascular disorder, hypertensive disorder, vascular disorder | Not yet recruiting | Phase 1 | 2025-12-31 | NCT07312799 | |
| A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, cardiovascular disorder, hyperlipidemia, hypertensive disorder, metabolic disease, vascular disorder | Not yet recruiting | Phase 1 | 2025-12-31 | NCT07312773 | |
| A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A | Mixed Dyslipidemia | Not yet recruiting | Phase 1 | 2025-12-04 | NCT07152873 | |
| The Food Effect on PK Characteristics and Safety Profiles of PA-111 | Mixed Dyslipidemia | Not yet recruiting | Phase 1 | 2025-05-16 | NCT06976489 | |
| A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A | Mixed Dyslipidemia | Recruiting | Phase 1 | 2025-04-17 | NCT06932705 | |
| A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A | Deglutition Disorders, Digestive System Diseases, digestive system disorder, dyskinesia of esophagus, esophageal disorder, gastroesophageal reflux disease | Not yet recruiting | Phase 1 | 2025-04-08 | NCT06916130 | |
| A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284 | Primary Hypercholesterolaemia | Recruiting | Phase 1 | 2025-03-20 | NCT06884098 | |
| A Study to Evaluate the Efficacy and Safety of AD-218 | Mixed Dyslipidemia | Recruiting | Phase 3 | 2025-02-05 | NCT05400317 | |
| A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B | cardiovascular disorder, essential hypertension, hypertensive disorder, vascular disorder | Recruiting | Phase 3 | 2025-02-04 | NCT06441630 |